Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Redefining Healthcare: Prioritizing in Remote Patient Monitoring

Remote Patient Monitoring (RPM) is using digital tools to provide care beyond traditional clinical settings, improving patient outcomes and reducing costs. Tools like Tripolo are helping these efforts by integrating technology into smart homes and facilitating personal communication between patients and providers. This shift towards digital solutions in healthcare supports patient independence and caters to those with chronic conditions or who are aging in place.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Healthcare ·
Share
Redefining Healthcare: Prioritizing in Remote Patient Monitoring

Key takeaways

01

Remote Patient Monitoring (RPM) improves patient care by leveraging digital tools outside of traditional clinical settings.

02

Clinically validated and affordable digital tools enable effective healthcare delivery, particularly for chronic and aging patients.

03

Platforms like Tripolo enhance healthcare accessibility by integrating RPM with smart home technology.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

This report underscores the potential of remote patient monitoring (RPM) as a breakthrough element in patient-centric healthcare. It discusses the incorporation of digital technology for monitoring patients outside of clinical settings, with various affordable, clinically validated tools playing a vital role in improving patient outcomes. The report draws on industry-leading platforms, such as Tripolo and their customized offerings, providing insights into the overarching impact of RPM in healthcare.

Introduction

Reflecting the strategic emphasis on patient independence and improved clinical outcomes, this case study explores evolving RPM technology, particularly for chronic and aging patients. By analyzing the application of these digital tools and their contribution to the healthcare landscape, we assess their relevance in democratizing patient care.

Findings

For patients experiencing chronic conditions or aging in place, conventional in-person care is often impractical. Herein lies the value of RPM that allows effective monitoring outside of clinical settings. The effectiveness of such monitoring is contingent on the accuracy of the technology, highlighting the importance of clinically validated tools. Integrating these tools into smart connected homes paves the way for cost-effective and convenient healthcare solutions.

Discussion

A shift towards patient independence and improved clinical outcomes necessitates an exploration of alternative solutions. One viable alternative is the consolidation of smart connected healthcare tools with smart homes, encouraging affordable and convenient home-bound patient care. As a testament to the potential of this digital transformation, platforms like Tripolo are ameliorating healthcare accessibility by facilitating personalized patient-provider communication.

Leveraging affordable and clinically validated tools not only reinvents the provision of healthcare but also attunes it to the changing needs of patients, particularly those with chronic conditions or aging in place.

Conclusion

The value of integrating digital tools in RPM is readily apparent in facilitating patient care. Leveraging affordable and clinically validated tools not only reinvents the provision of healthcare but also attunes it to the changing needs of patients, particularly those with chronic conditions or aging in place.

Recommendations

Healthcare professionals should pivot towards adopting digital tools for RPM, placing emphasis on patient-centric care, clinical validation, and affordability of these tools. Platforms like Tripolo can serve as an effective starting point for this transformation. Continuous assessment and improvement of these technological applications will ensure their sustained relevance in improving patient outcomes.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

H
Healthcare
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

H
Healthcare

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512